| Author | Study Design | Study Setting | Duration of Follow up | Data Source | Outcome Measure | Participants (type and No) | Findings (TDF vs. ZDV) |
|---|---|---|---|---|---|---|---|
| Scarsi KK 2015 [15] | Retrospective cohort | Nigeria | 105 months | Defined cohort | Virologic failure (VF) (>1000 copies/ml) | Age ≥18yr (5547) |
159/1484 vs. 298/4063a at 6 month |
| ART switch not due to VF | 256/1484 vs. 622/4063b | ||||||
| Discontinuation* | 308/1484 vs. 649/4063a | ||||||
| Labhartd 2015 [26] | Cross-sectional | Multicentre | Data taken from defined cohort | Virologic success (<80 copies/ml) | Age ≥16yr (1539) |
930/997 vs. 473/542a | |
| Clinical failure | 2.8% vs. 2.7%b | ||||||
| Immunologic failure | 4.6% vs. 4.8%b | ||||||
| Velen 2013 [27] | Prospective cohort | South Africa | 37 months | ART program | Single drug substitution | Age ≥17yrs (2017) |
10/665 vs. 95/1352a |
| Mortality in PYs | 9.2/100PYs vs. 11.1/100PYsa | ||||||
| Loss from care in PYs | 9.8/100PYs vs. 9.5/100PYs | ||||||
| Viral suppression (<400 copies/ml at 24 months) | 46% in TDF group vs. 42% of participants in ZDV group a | ||||||
| Chi 2010 [28] | Retrospective cohort | Zambia | 18 months | ART program | Mortality | Age >16yrs (8518) |
332/6284 vs. 90/2234b |
| Drug substitution in PYs | 9.0/100PYs vs. 27.0/100PYsa | ||||||
| Creatinine clearance (Clcr<50ml/min) | 73//2759 vs. 5/523a at 6 month while 30/960 vs. 7/294b at 12 month respectively | ||||||
| Program failure** | 32.2/100PYs vs. 28.1/100PYsb | ||||||
| Mean change in Clcr (ml/min) | -14.7 vs. -12.7b at 6 month and -22.0 vs. -23.7b at 12 month | ||||||
| Chi 2011 [29] | Retrospective cohort | Zambia | 40 months | ART program | Mortality | Age >16yrs (18866) |
767/15100 vs. 143/3766b |
| Program failure** | 4359/15100 vs. 1412/3766b | ||||||
| Thuppal 2015 [30] | Retrospective cohort | India | 36 months | ART program | Adverse drug events | Adults (221) |
10/92 vs. 61/129a |
| Opportunistic infections | 17/92 vs. 26/129b | ||||||
| Hospitalization | 18/92 vs. 30/129b | ||||||
| Mean change in CD4 (SD) | 388(198) vs. 359(220)b | ||||||
| Mean change in BMI (SD) | 3.6(3) vs. 1.8 (2.5)a | ||||||
| Amoroso 2012 [31] | cross-sectional | Multicentre | 48 months | Defined cohort | Viral suppression (<400 copies/ml) after 9 months | Age ≥16yrs (1819) |
597/668 vs. 1008/1151a |
| Damtew 2014 [32] | Retrospective cohort | Ethiopia | 60 months | ART program | Mortality | Age ≥15yr (485) |
25/233 vs. 30/252b |
| Eluwa 2012 [33] | Retrospective cohort | Nigeria | 36 months | ART program | Adverse drug events | Age ≥15yr (1420) |
1/46 vs. 34/1374a |
| Ayele T 2017 [34] | Retrospective cohort | Ethiopia | 24 months | ART program | Mortality | Age ≥14yr (280) |
5/140 vs. 6/140b |
| Opportunistic infections | 20/140 vs. 25/140a | ||||||
| Ayele 2017 [35] | Retrospective cohort | Ethiopia | 24 months | ART program | Mean change in CD4 (SD) | Age ≥14yr (280) |
321.7(164.8) vs. 299.4(126.1)a |
| von Braun 2017 [36] | Cross-sectional | Uganda | 24 months | Defined cohort | VF (>1000 copies/ml) | TB/HIV co-infected adults (Age ≥18yrs) (148) |
14/119 vs. 7/29c at 6 month |
| Woldegebriel 2016 [37] | Cross-sectional | Ethiopia | 96 months | ART program | Adverse drug events | Age ≥18yrs (183) |
1/90 vs. 11/93a |
| Parkes-ratanshi 2015 [38] | Nested cohort | Uganda | 48 months | Defined cohort | Anemia (Hgb<6.5g/dl) | Adults (224) |
5/63 vs. 18/161c |
| Mean change in Hgb (IQR) | 0.84(0.51-1.45) vs. 1(0.91-1.52)c at 48 weeks | ||||||
| PrayGod 2017 [39] | Cross-sectional | Tanzania | 40 months | Defined cohort | prediabetes or diabetes development | Malnourished adults (260) | 30/135 vs. 29/125b |
| Baynes 2017 [40] | Cross-sectional [] | Ethiopia | 60 months | ART program | Serum creatinine (SD) | Age>15years (245) |
0.83(0.36) vs. 0.87(0.38)a |
| Blood urea nitrogen | 11.74(4.17) vs. 14.86(7.53)a | ||||||
| ALT | 31.1(4.2) vs. 32.2 (2.3)b | ||||||
| Biset 2016 [41] | Cross-sectional | Ethiopia | 42 months | ART program | Treatment failure | Age ≥18yr (330) |
11/155 vs. 3/175c |
| Immunologic failure | 10/155 vs. 3/175c | ||||||
| VF (<5000 copies/ml) | 10/155 vs. 2/175c |